& let investors know which direction the company will be taking ? This kind of action is not fair to shareholders @ all . They only have 3 options to get Plecanatide to market, so pick one & lets move on. Long SGYP
You don't think investors will take profits when a stock climbs so fast ?? been in markets 25 years, better pull your head out of your #$%$!
buy stocks under a dollar, the risk to companies doing reverse stock splits are very high !!! I wouldn't buy this stock with free money from my worst enemy.
Sentiment: Strong Sell
PACB has built a much better mousetrap than ILMN, so if you cant beat em .. join em, I see a 1.5b offer coming soon. Long PACB
Sentiment: Strong Buy
The only news will not be until July & then in Aug 2016 re: the final results from the IBS-C study, after that I hope to hear BO news!!!
Most investors think that Shire will be the buyer of SGYP, but if this assumption is correct, then why would they need to hire Marino Garcia, SGYP knows what their company is worth in the event of a sale, so don't think Shire is the buyer. SGYP has already showed their hand a year ago & stated they was putting company up for sale, they never said they was looking for a partner, although more value would be created for company & shareholders , so it seems to me that hiring more people would indicate a partnership , or borrowing the 200-300m & collecting all profits is more likely ? Long SGYP
The most positive case I can make @ this time is that Antares is acquired in 2017; let’s look at the example of Avanir to judge what a takeover price could be. Avanir launched its only product, Nuedexta for pseudobulbar affect in 2010. The sales growth due to Nuedexta was as follows: $10 million in 2011, $41 million in 2012, $75 million in 2013 and an estimated $111 million in 2014. This is not dissimilar to the sales trajectory I am forecasting for Antares from 2014 through 2017. Avanir was acquired by Otsuka in December 2014 for $3.5 billion which was 32 times expected 2014 sales. There are many differences between Avanir and Antares of which the most striking are that Nuedexta has a much better patent position than the products of Antares, but Antares has a much, much broader array of product candidates. The 32 times market capitalization to sales purchase price paid by Otsuka seems extremely high, but even half that price (as judged by multiple of sales) would be very rewarding. After cutting out redundant costs, Antares could be an accretive acquisition for one of many specialty pharmaceutical companies with Teva probably being at the top of the list. At 11 times market capitalization to sales, the stock price would be $10.00.
These reverse splits are wiping out shareholders, my cost basis will go from 3.45 to 34 if a 1 for 10 reverse split happens , although a 1 for 5 would do it. Not really wanting to take a $1,900 loss, but not sure its worth to keep buying down cost basis, any ray of hope ?
Gilder Gagnon Howe & Co. LLC Invests $43,105,000 in Pacific Biosciences of California (PACB)
Posted by Seth Hatwan on Mar 7th, 2016 // Strong Buy
Pacific Biosciences of California logoGilder Gagnon Howe & Co. LLC acquired a new stake in Pacific Biosciences of California (NASDAQ:PACB) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 3,282,966 shares of the company’s stock, valued at approximately $43,105,000. Gilder Gagnon Howe & Co. LLC owned 4.26% of Pacific Biosciences of California as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also acquired new stakes or increased their stakes in the company. Geduld E E acquired a new position in Pacific Biosciences of California during the fourth quarter valued at $853,000. Oxford Asset Management acquired a new position in Pacific Biosciences of California during the fourth quarter valued at $2,195,000. Swiss National Bank increased its position in Pacific Biosciences of California by 27.0% in the fourth quarter. Swiss National Bank now owns 84,446 shares of the company’s stock valued at $1,109,000 after buying an additional 17,946 shares during the last quarter. Asymmetry Capital Management L.P. acquired a new position in Pacific Biosciences of California during the fourth quarter valued at $1,908,000. Finally, California State Teachers Retirement System increased its position in Pacific Biosciences of California by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 112,214 shares of the company’s stock valued at $1,473,000 after buying an additional 1,998 shares during the last quarter.
Sentiment: Strong Buy
1.Terex (TEX) (NEW!)
2.Progress Software (PRGS)
3.CyberArk Software (CYBR)
5.The Fresh Market (TFM)
7.Marvell (MRVL) (NEW!)
9.Pacific Bio (PACB) (NEW!)
10.Norfolk Southern (NSC)
Sentiment: Strong Buy
I own a lot of ATRS like many investors & worried about the stock price being under a dollar, do hope they have other methods ? We need a decent size investment soon!!!
I'm a trader so 5k shares with a $7 upside = about $25k in peanuts lol after uncles part. Not worried about ever losing money on PACB, but would rather not hold too long in this wild market!!
CSK was a brilliant move for ORLY, they needed stores in the West & man did they get some , the build out organically would be 5-7 years there which would be much longer on the East coast to acquire thousands of stores so all the more reason to do the Acquisition. AAP is much like ORLY so they are preferred in the deal by shareholders same as CSK. ORLY does it better than anyone !! I've been involved in many BO's with ORLY & they are flawless & every time ORLY announces an acquisition their stock soars, so I see ORLY easily going up $30-40 a share , although maybe not as much because of the bond offering which is the first step for this large takeover. PS: I am making a 5 year price call on ORLY stock & saying that it will be $485 by March 2021.